Barclays’s Replimune Group REPL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.52M Sell
265,800
-50,100
-16% -$634K ﹤0.01% 2234
2026
Q2
$3.5M Buy
315,900
+70,900
+29% +$434K ﹤0.01% 2033
2026
Q1
$1.87M Buy
+245,000
New +$1.87M ﹤0.01% 2389
2025
Q4
– Sell
-37,000
Closed -$155K – 5598
2025
Q3
$155K Sell
37,000
-38,900
-51% -$249K ﹤0.01% 4441
2025
Q2
$705K Buy
+75,900
New +$662K ﹤0.01% 3560

Other funds holding REPL

Barclays's REPL Position: Q3 2026 in Review

Barclays increased its Replimune Group (REPL) stake by 47% in Q3 2026, buying an estimated $1.34M and bringing the position to 332,977 shares worth $4.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2112.

Barclays first reported a position in REPL in Q3 2018 and has held it in 33 quarters since. 206 funds tracked by Wall St. Rank hold REPL as of Q3 2026.

  • Barclays held 332,977 shares of Replimune Group worth $4.41M as of Q3 2026.
  • Barclays bought 105,914 Replimune Group shares in Q3 2026, an estimated $1.34M.
  • Replimune Group made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2112 holding.
  • Barclays first reported a position in Replimune Group in Q3 2018 and has held it in 33 quarters since.
  • 206 funds tracked by Wall St. Rank held Replimune Group as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.